SEATTLE GENETICS INC (71) | Business Operations (16)

Browse by Subcategory

Recent Contracts

Collaboration and License Agreement dated January 7, 2007 between (Filed With SEC on February 9, 2022)
Tenth Amendment to Development and Supply Agreement, effective as of December 26, 2016 between (Filed With SEC on February 9, 2022)
Commercial Supply Agreement between Hovione Farmaciencia, SA and Seagen Inc. dated July 1, 2021 (Filed With SEC on October 28, 2021)
Ninth Amendment to Development and Supply Agreement effective as of August 28, 2016 between Seagen Inc. (f/k/a Seattle Genetics, Inc.) and AbbVie Inc. (formerly part of Abbott... (Filed With SEC on October 28, 2021)
Commercial Supply Agreement dated December 1, 2010 between (Filed With SEC on February 12, 2021)
First Amendment to Commercial Supply Agreement effective as of January 20, 2014 between (Filed With SEC on February 12, 2021)
Second Amendment to Commercial Supply Agreement effective as of December 2, 2016 between (Filed With SEC on February 12, 2021)
Sixth Amendment to Development and Supply Agreement dated November 18, 2010 between (Filed With SEC on February 12, 2021)
License and Collaboration Agreement relating to ladiratuzumab vedotin dated September 13, 2020 between Seagen Inc. (f/k/a Seattle Genetics, Inc.) and Merck Sharp & Dohme Corp (Filed With SEC on October 30, 2020)
Commercial Supply Agreement dated June 13, 2019 between Seattle Genetics, Inc. and Esteve Quimica, S.A (Filed With SEC on July 31, 2020)
Commercial Supply Agreement dated February 20, 2020 between Seattle Genetics, Inc. and Corden Plankstadt (Filed With SEC on July 31, 2020)
Commercial Supply Agreement dated April 2, 2020 between Seattle Genetics, Inc. and Sterling Pharma Solutions Limited (Filed With SEC on July 31, 2020)
Eleventh Amendment to Development and Supply Agreement effective July 12, 2018 between Seattle Genetics, Inc. and AbbVie Inc. (formerly part of Abbott Laboratories, Inc.) (Filed With SEC on February 6, 2020)
Collaboration Agreement between Seattle Genetics, Inc. and Millennium Pharmaceuticals, Inc. (a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited) dated December 14,... (Filed With SEC on February 6, 2020)
Third Amendment to Commercial Supply Agreement effective as of July 1, 2019 between Seattle Genetics, Inc. and SAFC, an operating division of Sigma-Aldrich, Inc (Filed With SEC on October 30, 2019)
Twelfth Amendment to Development and Supply Agreement, effective as of April 25, 2019 between Seattle Genetics, Inc. and AbbVie, Inc. (formerly part of Abbott Laboratories, Inc.) (Filed With SEC on July 16, 2019)